Plateaus and comparison with ketamine

DXM FAQ 1997: selective audit by topic

The limits of descriptive categories and the conditions of a direct comparison in research.

Plateaus as descriptions of experience

These categories help describe reports of experience. Their boundaries vary with metabolism, formulation, combinations and individual characteristics.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: CYP2D6 studies and changes in the DXM/DXO balance show qualitative variability in responses. This calls for caution when applying the historical classification to an individual.

Limits of the conclusion: Clinical conclusions require measured exposures and endpoints. A plateau description remains a subjective category.

Sources: William White — historical DXM FAQ Rüdesheim — pharmacokinetic model Zawertailo — metabolism and effects Zawertailo — CYP2D6 inhibition

Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 The FAQ distinguishes plateaus and allows intermediate states.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.3.1 · Plateaus 1-3: Multiple Receptors

A direct comparison of DXM and ketamine

A controlled study now includes a direct comparison with DXM. It examined abuse potential and subjective effects under specific conditions.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: In Shram’s paper, the principal comparison concerned ketamine and placebo; DXM served as an additional exploratory comparator.

Limits of the conclusion: The results apply to the selected participants, administration routes and measures. Comparing all forms and varieties of dissociative experience remains a broader task.

Sources: Shram — ketamine comparison

Historical paraphrase · FAQ 4.0 · 1997 · §10.6 The FAQ notes limits to the similarity between DXM and ketamine.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.6 · How Does DXM Compare to Other Dissociatives at These Receptors?

Sources for this topic
  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Rüdesheim — pharmacokinetic model — PubMed abstract
  3. Zawertailo — metabolism and effects — PubMed abstract
  4. Zawertailo — CYP2D6 inhibition — PubMed abstract
  5. Shram — ketamine comparison — PubMed abstract

All update topics · Review coverage

Reference

Open the source and related combinations →